Occam Recruits Sapna Srivastava to the Board of Nuvalent
Nuvalent, an F-Prime/Deerfield investment, develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events and drive more durable responses. The company went public in 2021 generating $166M.
In late 2021, Occam recruited Sapna Srivastava, PhD to the Board of Nuvalent. Sapna began her career as an equity analyst on Wall Street before taking on operating CFO roles at innovative biotechs like eGenesis, VelosBio, and Intellia.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.